A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma

Sorafenib 400 mg BID cannot be recommended as maintenance therapy for patients with OC in complete remission. Assessment of efficacy was limited by the high rate of dose reductions and early discontinuations.